Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, two stages, open-label, pilot study to investigate the
efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients. The BEV is the best
physician's choice of standard of care for rGBM after prior radiotherapy and temozolomide
chemotherapy in the LinKou Chang Gung Memorial Hospital. Eligible patients will be enrolled
through the process of informed consent.